EMRICASAN (IDN-6556, PF-03491390) is a potential drug invented in 1998 by Idun Pharmaceuticals. [1][2] The drug was acquired by Pfizer in 2005 [3] and then sold to Conatus Pharmaceuticals in 2010.[4] Conatus in turn licensed emricasan to Novartis in 2017 for exclusive development and commercialization.[5]
